STERIS plc’s fiscal Q3 2026 results demonstrate sustained momentum across its Healthcare, Advanced Sterilization Technologies (AST), and Life Sciences segments. Revenue growth was driven by volume increases and pricing strength, while operational productivity improvements helped mitigate inflation and tariff headwinds. The company’s integrated business model leverages recurring service revenues alongside capital equipment sales, maintaining competitive positioning despite emerging technology threats and regulatory complexity. Going forward, industry dynamics such as evolving EO sterilization regulations and geopolitical risks remain watchpoints alongside innovation pipeline execution.